Management Team and Board

Dr Daniel Gooding, Chief Executive Officer

Dan brings over 17 years experience in commercialisation and business development within the pharmaceutical industry, having received his PhD in Chemistry from Leeds University. Dr Gooding began his career in commercial roles with pharmaceutical excipients companies including FMC and Dow Corning. At Accelrys Dan was responsible for sales across the UK and Southern Europe driving new business development within the emerging nanotechnology, drug delivery and formulation sectors. Dan has also led successful licensing deals within the pharmaceutical industry with companies such as Johnson & Johnson and AstraZeneca. Dan is a cofounder of Nuformix.

Dr Joanne Holland, Chief Scientific Officer

Joanne received her PhD in Chemistry from Leeds University. She joined the process R&D group at Millennium Pharmaceuticals before moving to a combined research and commercial role at Stylacats Ltd. After this Joanne worked for Medeor Pharma Ltd and Medeor Ltd undertaking commercial and scientific research on new business and investment opportunities. Joanne is a cofounder of Nuformix, and is responsible for R&D, intellectual property and regulatory issues.

Kirk Siderman-Wolter, Financial Director

Kirk is a Chartered Accountant, with extensive experience of both private and public sectors in the UK, Europe, Asia and the Americas. He has worked on large scale capital and infrastructure projects, contract renegotiation, post-merger integration and transformation programmes with Cable & Wireless, O2 and Vodafone as well as holding posts with the Ministry of Justice, BIS, the Home Office and the Foreign & Commonwealth Office. Kirk has an MBA from the London Business School and is a Fellow of the Royal Society for Arts, Manufactures and Commerce and has been a non-executive on several boards.

Dr David Tapolczay, Non-Executive Chairman

CEO of Medical Research Council Technology, previously CSO at Sigma Aldrich and VP Technology Development at GSK. Dr Tapolczay has over 20 years experience of Pharmaceutical and Agrochemical R&D management and licensing. Past roles include Chairman of Pharmorphix, CEO of Stylacats, Vice President Pharmaceutical Sciences at Millennium, Vice President R&D Cambridge Discovery Chemistry, and worldwide head of chemistry for Zeneca agrochemicals and senior manager of chemical development for Glaxo. Dr Tapolczay brings a wealth of experience in creating value in early-stage companies and is a cofounder of Nuformix.

Prof John Lidgey, Non-executive Director

John Lidgey, formerly Chairman of Levrett plc, is a Non-Executive Director with Nuformix plc. The majority of his career was spent as an academic, initially with the University of Newcastle, Australia and then at Oxford Brookes University. His principal area of expertise is electronic engineering and he has gained significant international recognition for his research achievements in analogue circuit and system design, with applications covering many sectors including bio-medical electronics and diagnostic instrumentation. He is Emeritus Professor of Electronic Engineering at Oxford Brookes University.